ID

12474

Descrizione

The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome. The study may also provide information about the effect of vorapaxar on preventing heart attack and stroke in this subject population. https://clinicaltrials.gov/ct2/show/NCT00684203

collegamento

https://clinicaltrials.gov/ct2/show/NCT00684203

Keywords

versioni (2)
  1. 28/07/15 28/07/15 -
  2. 21/11/15 21/11/15 -
Caricato su

21 novembre 2015

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Vorapaxar Acute Coronary Syndrome NCT00684203

Inglese

Eligibility criteria

1 moduli  
  1. StudyEvent: ODM
    1. Eligibility criteria
Inclusion Criteria
Descrizione

Inclusion Criteria

Men and women aged 18 years or more
Descrizione

Men and women aged 18 years or more

Tipo di dati

boolean

Alias
UMLS CUI-1
C0001779
with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization
Descrizione

with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization

Tipo di dati

boolean

Alias
UMLS CUI-1
C0008031
with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization
Descrizione

with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization

Tipo di dati

boolean

Alias
UMLS CUI-1
C0151744
Participants who are planned to undergo PCI will be the target participants
Descrizione

Participants who are planned to undergo PCI will be the target participants

Tipo di dati

boolean

Alias
UMLS CUI-1
C1532338
Elevated troponin I
Descrizione

Elevated troponin I

Tipo di dati

boolean

Alias
UMLS CUI-1
C0920210
creatinine kinase MB isozyme greater than the site's upper limit of normal (ULN)
Descrizione

creatinine kinase MB isozyme greater than the site's upper limit of normal (ULN)

Tipo di dati

boolean

Alias
UMLS CUI-1
C0523584
ST segment depression >= 0.1 mV (>=1 mm)
Descrizione

ST segment depression >= 0.1 mV (>=1 mm)

Tipo di dati

boolean

Alias
UMLS CUI-1
C0520887
transient (<30 minutes) ST segment elevation >= 0.1 mV (>=1 mm) in at least 2 contiguous leads
Descrizione

transient (<30 minutes) ST segment elevation >= 0.1 mV (>=1 mm) in at least 2 contiguous leads

Tipo di dati

boolean

Alias
UMLS CUI-1
C0520886
Willing to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and all visit schedules.
Descrizione

Willing to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and all visit schedules.

Tipo di dati

boolean

Alias
UMLS CUI-1
C0021430
Women of child-bearing potential (all postmenarchal women who are <1 years menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 60 days after stopping the medication.
Descrizione

Women of child-bearing potential (all postmenarchal women who are <1 years menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 60 days after stopping the medication.

Tipo di dati

boolean

Alias
UMLS CUI-1
C0700589
Exclusion Criteria
Descrizione

Exclusion Criteria

Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)
Descrizione

Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)

Tipo di dati

boolean

Alias
UMLS CUI-1
C0549206
known hypersensitivity to any component of the current investigational product;
Descrizione

known hypersensitivity to any component of the current investigational product;

Tipo di dati

boolean

Alias
UMLS CUI-1
C0013182
Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment
Descrizione

Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment

Tipo di dati

boolean

Alias
UMLS CUI-1
C0422740
History of a bleeding diathesis
Descrizione

History of a bleeding diathesis

Tipo di dati

boolean

Alias
UMLS CUI-1
C3251812
evidence of active abnormal bleeding within 30 days before enrollment
Descrizione

evidence of active abnormal bleeding within 30 days before enrollment

Tipo di dati

boolean

Alias
UMLS CUI-1
C0019080
History of a hemorrhagic stroke at any time
Descrizione

History of a hemorrhagic stroke at any time

Tipo di dati

boolean

Alias
UMLS CUI-1
C0559159
Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) while receiving therapy;
Descrizione

Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) while receiving therapy;

Tipo di dati

boolean

Alias
UMLS CUI-1
C0020538
Major surgery within 2 weeks prior to enrollment
Descrizione

Major surgery within 2 weeks prior to enrollment

Tipo di dati

boolean

Alias
UMLS CUI-1
C0679637
Known platelet count <100,000/mm^3
Descrizione

Known platelet count <100,000/mm^3

Tipo di dati

boolean

Alias
UMLS CUI-1
C0032181
Uncontrolled cardiac arrhythmia;
Descrizione

Uncontrolled cardiac arrhythmia;

Tipo di dati

boolean

Alias
UMLS CUI-1
C0003811
Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]), dysproteinemia, nephrotic syndrome, or other renal disease;
Descrizione

Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]), dysproteinemia, nephrotic syndrome, or other renal disease;

Tipo di dati

boolean

Alias
UMLS CUI-1
C0035078
Active or chronic hepatobiliary or hepatic disease
Descrizione

Active or chronic hepatobiliary or hepatic disease

Tipo di dati

boolean

Alias
UMLS CUI-1
C0085605
Anticipated staged PCI
Descrizione

Anticipated staged PCI

Tipo di dati

boolean

Alias
UMLS CUI-1
C1532338
Anticipated intracoronary brachytherapy
Descrizione

Anticipated intracoronary brachytherapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2145202
Concurrent or anticipated treatment with warfarin
Descrizione

Concurrent or anticipated treatment with warfarin

Tipo di dati

boolean

Alias
UMLS CUI-1
C0043031
Concurrent or anticipated treatment with factor Xa inhibitor after enrollment
Descrizione

Concurrent or anticipated treatment with factor Xa inhibitor after enrollment

Tipo di dati

boolean

Alias
UMLS CUI-1
C2825027
Concurrent or anticipated treatment with direct thrombin inhibitor after enrollment
Descrizione

Concurrent or anticipated treatment with direct thrombin inhibitor after enrollment

Tipo di dati

boolean

Alias
UMLS CUI-1
C3536847
Concurrent or anticipated treatment with or antiplatelet agents after enrollment
Descrizione

Concurrent or anticipated treatment with or antiplatelet agents after enrollment

Tipo di dati

boolean

Alias
UMLS CUI-1
C1096021
Ritorna all'inizio della pagina

Similar models

Eligibility criteria

1 moduli
  1. StudyEvent: ODM
    1. Eligibility criteria
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Inclusion Criteria
Age
Item
Men and women aged 18 years or more
boolean
C0001779 (UMLS CUI-1)
Chest pain
Item
with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization
boolean
C0008031 (UMLS CUI-1)
Myocardial Ischemia
Item
with history of cardiac ischemia related chest discomfort of > 10 minutes duration < 24 hours prior to randomization
boolean
C0151744 (UMLS CUI-1)
PCI
Item
Participants who are planned to undergo PCI will be the target participants
boolean
C1532338 (UMLS CUI-1)
Troponin I
Item
Elevated troponin I
boolean
C0920210 (UMLS CUI-1)
CK-MB
Item
creatinine kinase MB isozyme greater than the site's upper limit of normal (ULN)
boolean
C0523584 (UMLS CUI-1)
ST-segment depression
Item
ST segment depression >= 0.1 mV (>=1 mm)
boolean
C0520887 (UMLS CUI-1)
ST-segment elevation
Item
transient (<30 minutes) ST segment elevation >= 0.1 mV (>=1 mm) in at least 2 contiguous leads
boolean
C0520886 (UMLS CUI-1)
Informed consent
Item
Willing to give appropriate informed consent and complete all study-related procedures, and able to adhere to dosing and all visit schedules.
boolean
C0021430 (UMLS CUI-1)
Contraception
Item
Women of child-bearing potential (all postmenarchal women who are <1 years menopausal or who have not had surgical sterilization or a hysterectomy are considered to be women of child-bearing potential) must agree to use a medically accepted method of contraception while receiving protocol-specified medication, and for 60 days after stopping the medication.
boolean
C0700589 (UMLS CUI-1)
Item Group
Exclusion Criteria
Pregnancy
Item
Pregnant and nursing mothers (premenopausal women should have a negative pregnancy test result confirmed before enrollment)
boolean
C0549206 (UMLS CUI-1)
Medication allergy
Item
known hypersensitivity to any component of the current investigational product;
boolean
C0013182 (UMLS CUI-1)
Study patient
Item
Participation in a study of experimental therapy or use of any investigational drug within 30 days before enrollment
boolean
C0422740 (UMLS CUI-1)
Bleeding risk
Item
History of a bleeding diathesis
boolean
C3251812 (UMLS CUI-1)
Hemorrhage
Item
evidence of active abnormal bleeding within 30 days before enrollment
boolean
C0019080 (UMLS CUI-1)
History of stroke
Item
History of a hemorrhagic stroke at any time
boolean
C0559159 (UMLS CUI-1)
Hypertension
Item
Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) while receiving therapy;
boolean
C0020538 (UMLS CUI-1)
Major surgery
Item
Major surgery within 2 weeks prior to enrollment
boolean
C0679637 (UMLS CUI-1)
Platelet count
Item
Known platelet count <100,000/mm^3
boolean
C0032181 (UMLS CUI-1)
Cardiac arrhythmia
Item
Uncontrolled cardiac arrhythmia;
boolean
C0003811 (UMLS CUI-1)
Kidney failure
Item
Known impairment of renal function (serum creatinine >2.0 mg/dL [>176.8 umol/L]), dysproteinemia, nephrotic syndrome, or other renal disease;
boolean
C0035078 (UMLS CUI-1)
Liver failure
Item
Active or chronic hepatobiliary or hepatic disease
boolean
C0085605 (UMLS CUI-1)
PCI
Item
Anticipated staged PCI
boolean
C1532338 (UMLS CUI-1)
Intracoronary brachytherapy
Item
Anticipated intracoronary brachytherapy
boolean
C2145202 (UMLS CUI [1])
Warfarin
Item
Concurrent or anticipated treatment with warfarin
boolean
C0043031 (UMLS CUI-1)
Factor Xa inhibitor
Item
Concurrent or anticipated treatment with factor Xa inhibitor after enrollment
boolean
C2825027 (UMLS CUI-1)
Direct thrombin inhibitor
Item
Concurrent or anticipated treatment with direct thrombin inhibitor after enrollment
boolean
C3536847 (UMLS CUI-1)
Antiplatelet therapy
Item
Concurrent or anticipated treatment with or antiplatelet agents after enrollment
boolean
C1096021 (UMLS CUI-1)
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial